GHK-Cu

GHK-Cu

100MG

This GHK-Cu dosage chart explains a 50 mg vial prepared to a final volume of 3.0 mL for a concentration of 16.67 mg/mL. The GHK-Cu dosage protocol examples below cover 1.0 mg, 1.5 mg, and 2.0 mg amounts, with matching U-100 syringe units, reconstitution steps, supplies, and research context.

In stock   |   ≥99% catalog purity

SKU: N/A Categories: ,

Description

Product specification

Analytical Profile

Catalog data is presented for material identification and laboratory planning. Batch-specific documentation governs the supplied vial.

RESEARCH NAMEGHK-Cu · Copper Tripeptide-1
FORMATLyophilised powder · 50 mg vial
MOLECULAR FORMULAC14H23CuN6O4+
MOLECULAR MASS402.92 g/mol
CAS REGISTRY89030-95-5
ANALYTICAL IDENTITYHPLC + LC–MS
CATALOG CONDITIONSealed · dry · light-protected

PROTOCOL LITERACY

Reconstitution Sequence

This source-derived sequence assumes a 10 mg vial and a final reference volume of 1.0 mL. The supplied product documentation remains the controlling instruction.

01

Metabolic

Prepare 1.0 mL of bacteriostatic water with sterile equipment.

02

INTRODUCE SLOWLY

Direct the liquid toward the inside wall of the vial to limit foaming.

03

DISSOLVE GENTLY

Roll or swirl with care until the material is dissolved; do not shake.

04

LABEL AND PROTECT

Record the preparation date and keep the vial protected from light.

05

COLD STORAGE

Refrigerate at 2-8°C and use within the four-week reference window.

UNRECONSTITUTED MATERIAL

FOLLOW BATCH DOCUMENTATION

Keep frozen, dry, sealed, and protected from direct light. Minimise exposure to moisture.

After reconstitution

2-8°C

Keep refrigerated and light-protected. Stability depends on the diluent, concentration, pH, sterility, and container used.

Handling principle

DO NOT FREEZE

Minimise exposure to light and moisture, and avoid repeated freeze–thaw or temperature cycles.

PROTOCOL LITERACY

GHK CU DOSAGE CHART

A designed reference covering concentration, weekly schedule models, reconstitution, supply planning, storage, mechanism, study observations, and administration context. It is educational material—not an individualized regimen.

VIAL CONTENT

1.0 MG

+

REFERENCE DILUENT

1.0 MG

=

STOCK CONCENTRATION

1.0 MG/ML

U-100 SCALE

1 Unit = 0.01 ml 100 mcg

01

GRADUAL 8MG MODEL

02

12 MG TRIAL CONTEXT

EDUCATIONAL REFERENCE

GRADUAL DAILY MODEL

STUDY INTERVALSTAGEWEEKLY DOSEU-100 REFERENCESOLUTION VOLUME
01 WEEKS 1-4
INITIATION1.0 mg6 UNITS0.06 ML
02 WEEKS 5-8
ESCALATION 011.5 mg9 UNITS0.09 ML
03 Weeks 9-12+
INITIATION1.0 MG12 UNITS0.12 ML

01

REFERENCE ASSUMPTIONS

Every unit and volume value shown assumes a 10 mg vial prepared to a total reference volume of 1.0 mL.

02

MATERIAL BOUNDARY

This table does not provide preparation or administration instructions.

03

PROTOCOL CONTROL

Trial documentation and qualified clinical oversight—not this chart—must govern all dosing decisions.

Related products

  • BPC-157

    BPC-157

    View → This product has multiple variants. The options may be chosen on the product page
  • SELANK

    SELANK

    View → This product has multiple variants. The options may be chosen on the product page
  • BPC-157 + TB 500

    BPC-157 + TB 500

    View → This product has multiple variants. The options may be chosen on the product page
  • GLOW

    GLOW

    View → This product has multiple variants. The options may be chosen on the product page
  • KPV

    KPV

    View → This product has multiple variants. The options may be chosen on the product page
  • KLOW

    KLOW

    View → This product has multiple variants. The options may be chosen on the product page

Product Enquiry

Have a question about this product? Send us your enquiry and our team will get back to you shortly.

Enquire Product